Acquired hemophilia A is a rare bleeding diathesis caused by autoantibodies directed
against clotting factor VIII and associated with an increased morbidity and mortality. This …

Normal pregnancy is associated with profound alterations in the coagulation and fibrinolytic
systems. While these physiological procoagulant changes are aimed to minimise …

Acquired hemophilia A is a rare bleeding disorder caused by autoantibodies to coagulation
FVIII. Bleeding episodes at presentation are spontaneous and severe in most cases. Optimal …

Acquires hemophilia A (AHA) is rare bleeding condition commonly associated with
malignancy, autoimmune disease, or pregnancy. We report a case of a 69‐year‐old …

Acquired hemophilia A (AHA) is a rare bleeding disorder characterized by autoantibodies
directed against circulating coagulation factor (F) VIII. Typically, patients with no prior history …

A variety of autoimmune disorders have been reported after viral illnesses and specific
vaccinations. Cases of de novo immune thrombocytopenia (ITP) have been reported after …

Acquired haemophilia A (AHA) is a rare but often severe bleeding disorder caused by
autoantibodies against coagulation factor VIII (FVIII). AHA occurs more frequently in the …

In acquired hemophilia A (AHA), autoantibodies to coagulation factor VIII (FVIII) neutralize
FVIII activity leading to a potentially severe bleeding diathesis that carries a high rate of …

The occurrence of an inhibitor against coagulation factor V (FV) is a rare but challenging
condition, which may span from asymptomatic laboratory abnormalities to potentially life …

Rituximab is a monoclonal chimeric antibody to the CD20 antigen, which has proven to be
effective in the treatment of non-Hodgkin lymphomas. Recently, rituximab has also been …